X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8244) 8244
Book Review (2077) 2077
Publication (819) 819
Book / eBook (127) 127
Book Chapter (110) 110
Conference Proceeding (27) 27
Magazine Article (8) 8
Newsletter (3) 3
Newspaper Article (3) 3
Dissertation (2) 2
Data Set (1) 1
Paper (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7605) 7605
humans (5880) 5880
animals (3494) 3494
female (2468) 2468
male (2378) 2378
mice (1604) 1604
recombinant fusion proteins - therapeutic use (1486) 1486
middle aged (1376) 1376
proteins (1376) 1376
immunology (1302) 1302
adult (1242) 1242
treatment outcome (1042) 1042
recombinant fusion proteins - genetics (969) 969
aged (934) 934
biotechnology & applied microbiology (925) 925
recombinant fusion proteins - adverse effects (882) 882
analysis (847) 847
biochemistry & molecular biology (844) 844
recombinant fusion proteins - metabolism (827) 827
recombinant fusion proteins - administration & dosage (825) 825
research (824) 824
oncology (817) 817
health aspects (796) 796
recombinant proteins (756) 756
pharmacology & pharmacy (724) 724
expression (721) 721
cancer (717) 717
gene expression (697) 697
medicine, research & experimental (677) 677
antibodies, monoclonal - therapeutic use (671) 671
care and treatment (666) 666
hematology (632) 632
recombinant (607) 607
recombinant proteins - therapeutic use (591) 591
immunotherapy (586) 586
vaccines (575) 575
therapy (573) 573
recombinant fusion proteins - immunology (569) 569
antibodies (567) 567
surgery (553) 553
abridged index medicus (551) 551
molecular sequence data (533) 533
article (519) 519
amino acid sequence (508) 508
cell biology (506) 506
biotechnology (505) 505
in-vivo (505) 505
research article (505) 505
recombinant fusion proteins - pharmacology (504) 504
antigens (492) 492
medicine (487) 487
recombinant proteins - genetics (486) 486
transplantation (486) 486
rats (484) 484
multidisciplinary sciences (459) 459
physiological aspects (459) 459
recombinant proteins - metabolism (449) 449
cells (434) 434
microbiology (424) 424
safety (418) 418
clinical trials (408) 408
time factors (403) 403
adolescent (401) 401
dose-response relationship, drug (395) 395
drug therapy (385) 385
cell line (381) 381
immunosuppressive agents - therapeutic use (380) 380
genetic engineering (377) 377
medicine & public health (376) 376
science (372) 372
mice, inbred balb c (364) 364
escherichia-coli (363) 363
disease models, animal (356) 356
clinical trials as topic (355) 355
fusion protein (355) 355
efficacy (352) 352
enzymes (345) 345
retrospective studies (343) 343
t cells (338) 338
peptides (335) 335
double-blind (333) 333
genetic vectors (333) 333
medical research (333) 333
recombinant proteins - adverse effects (332) 332
recombinant fusion proteins - chemistry (328) 328
genetic aspects (327) 327
protein (326) 326
recombinant proteins - pharmacology (323) 323
genes (322) 322
recombinant fusion proteins (322) 322
biology (318) 318
cell line, tumor (318) 318
immunization (317) 317
escherichia coli (312) 312
aged, 80 and over (311) 311
gene therapy (311) 311
vaccination (309) 309
child (308) 308
life sciences (308) 308
antibodies, monoclonal - adverse effects (306) 306
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (76) 76
UofT at Mississauga - Stacks (27) 27
UofT at Scarborough - Stacks (20) 20
Engineering & Comp. Sci. - Stacks (13) 13
UTL at Downsview - May be requested (13) 13
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
St. Michael's College (John M. Kelly) - 2nd Floor (8) 8
St. Augustine's Seminary - Stacks (7) 7
Law (Bora Laskin) - Stacks (6) 6
Robarts - Stacks (6) 6
Earth Sciences (Noranda) - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Online Resources - Online (2) 2
Regis College - Stacks (2) 2
Baycrest Hospital - Stacks (1) 1
Gerstein Science - Searching (1) 1
OISE - Stacks (1) 1
Physics - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
Victoria University Emmanuel College - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8357) 8357
Spanish (19) 19
Chinese (17) 17
French (17) 17
German (16) 16
Japanese (13) 13
Italian (6) 6
Danish (4) 4
Czech (2) 2
Russian (2) 2
Dutch (1) 1
Finnish (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 12/2013, Volume 369, Issue 24, pp. 2313 - 2323
Journal Article
Vaccine, ISSN 0264-410X, 2012, Volume 31, Issue 3, pp. 524 - 532
Highlights ► This Phase 1 trial evaluated the safety and immunogenicity of an RSV (F) nanoparticle vaccine. ► The vaccine was well-tolerated and no related... 
Allergy and Immunology | Respiratory syncytial virus (RSV) | Palivizumab | Fusion protein (F protein) | Competitive ELISA | SF9 insect cell | Microneutralization | Aluminum phosphate | Anti-F IgG | Nanoparticle vaccine | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | NEUTRALIZING ANTIBODIES | IMMUNE GLOBULIN | COTTON RATS | INFLUENZA | RISK | IMMUNOLOGY | F-GLYCOPROTEIN | INFANTS | INFECTION | YOUNG-CHILDREN | Recombinant Fusion Proteins - immunology | Single-Blind Method | Biotechnology | Respiratory Syncytial Virus Vaccines - immunology | Adjuvants, Immunologic - administration & dosage | Aluminum Compounds - adverse effects | Phosphates - administration & dosage | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Male | Nanoparticles - adverse effects | Vaccines, Synthetic - immunology | Antibodies, Viral - blood | Adjuvants, Immunologic - adverse effects | Young Adult | Respiratory Syncytial Virus Vaccines - adverse effects | Sf9 Cells | Technology, Pharmaceutical | Vaccines, Virosome - immunology | Vaccines, Synthetic - adverse effects | Placebos - adverse effects | Adult | Female | Placebos - administration & dosage | Recombinant Fusion Proteins - administration & dosage | Vaccines, Virosome - administration & dosage | Vaccines, Synthetic - genetics | Vaccines, Virosome - genetics | Animals | Aluminum Compounds - administration & dosage | Phosphates - adverse effects | Vaccines, Virosome - adverse effects | Respiratory Syncytial Virus Vaccines - administration & dosage | Adolescent | Recombinant Fusion Proteins - genetics | Nanoparticles - administration & dosage | Vaccines, Synthetic - administration & dosage | Respiratory Syncytial Virus Vaccines - genetics | Antibodies, Neutralizing - blood | Virus diseases | Phosphates | Vaccines | Immunoglobulin G | Enzyme-linked immunosorbent assay | Proteins | Nanoparticles | Infections | Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, pp. CD007419 - CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | Quality of Life | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Index Medicus
Journal Article
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 06/2015, Volume 13, Issue 6, pp. 967 - 977
Prophylactic factor replacement, which prevents hemarthroses and thereby reduces the musculoskeletal disease burden in children with hemophilia A, requires... 
coagulation factor | hemophilia A | recombinant fusion proteins | VIII | children | prophylaxis | Children | Coagulation factor VIII | Recombinant fusion proteins | Hemophilia A | Prophylaxis | Recombinant Fusion Proteins - immunology | Factor VIII - immunology | Hemarthrosis - diagnosis | Age Factors | Recombinant Fusion Proteins - adverse effects | Factor VIII - pharmacokinetics | Humans | Child, Preschool | Half-Life | Male | Immunoglobulin Fc Fragments - administration & dosage | North America | Hemarthrosis - blood | Immunoglobulin Fc Fragments - immunology | China | Coagulants - administration & dosage | Factor VIII - adverse effects | Female | Hemophilia A - prevention & control | Coagulants - pharmacokinetics | Hemophilia A - diagnosis | Child | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Severity of Illness Index | Drug Administration Schedule | Europe | Risk Factors | Treatment Outcome | Hemophilia A - blood | Hemarthrosis - drug therapy | Recombinant Fusion Proteins - pharmacokinetics | Factor VIII - administration & dosage | South Africa | Infusions, Intravenous | Australia | Coagulants - adverse effects | Coagulants - immunology | Hemarthrosis - prevention & control | Hemophilia A - drug therapy | Antibodies, Neutralizing - blood | Prevention | Proteins | Care and treatment | Blood coagulation factor VIII | Hemophilia | Index Medicus
Journal Article
Ophthalmology, ISSN 0161-6420, 01/2014, Volume 121, Issue 1, pp. 193 - 201
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2015, Volume 372, Issue 13, pp. 1193 - 1203
Journal Article